Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) — Working Capital to Net Assets Ratio
Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has a Working Capital to Net Assets ratio of 40.2% as of June 2026. Working capital of CN¥764.26 Million (current assets of CN¥1.54 Billion minus current liabilities of CN¥772.87 Million) is measured against net assets of CN¥1.90 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Zhejiang Anglikang Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Working Capital to Net Assets (2014–2025)
This chart shows how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of June 2026, the ratio stands at 40.2%, reflecting working capital of CN¥764.26 Million against net assets of CN¥1.90 Billion CNY. For the complete balance sheet picture, see total assets of Zhejiang Anglikang Pharmaceutical Co Ltd.
Annual Working Capital to Net Assets for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Zhejiang Anglikang Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 36.0% | CN¥672.82 Million | CN¥1.87 Billion | CN¥1.49 Billion | CN¥813.03 Million | ▼ -0.4 pp |
| 2024 | 36.4% | CN¥655.33 Million | CN¥1.80 Billion | CN¥1.50 Billion | CN¥843.54 Million | ▼ -8.9 pp |
| 2023 | 45.3% | CN¥829.96 Million | CN¥1.83 Billion | CN¥1.56 Billion | CN¥731.97 Million | ▲ +5.0 pp |
| 2022 | 40.3% | CN¥663.37 Million | CN¥1.65 Billion | CN¥1.45 Billion | CN¥788.59 Million | ▼ -12.6 pp |
| 2021 | 52.9% | CN¥780.67 Million | CN¥1.47 Billion | CN¥1.38 Billion | CN¥595.29 Million | ▼ -8.6 pp |
| 2020 | 61.6% | CN¥848.21 Million | CN¥1.38 Billion | CN¥1.39 Billion | CN¥545.19 Million | ▲ +0.3 pp |
| 2019 | 61.2% | CN¥622.49 Million | CN¥1.02 Billion | CN¥977.66 Million | CN¥355.17 Million | ▲ +0.1 pp |
| 2018 | 61.1% | CN¥593.62 Million | CN¥970.93 Million | CN¥1.08 Billion | CN¥486.37 Million | ▲ +46.1 pp |
| 2017 | 15.0% | CN¥59.34 Million | CN¥394.37 Million | CN¥562.87 Million | CN¥503.53 Million | ▲ +9.8 pp |
| 2016 | 5.2% | CN¥17.15 Million | CN¥327.43 Million | CN¥401.42 Million | CN¥384.27 Million | ▲ +16.7 pp |
| 2015 | -11.4% | CN¥-30.20 Million | CN¥264.20 Million | CN¥462.03 Million | CN¥492.23 Million | ▲ +23.4 pp |
| 2014 | -34.8% | CN¥-75.55 Million | CN¥217.08 Million | CN¥401.18 Million | CN¥476.73 Million | — |